Riken Corporation

Astellas Pharma Gmbh

Kanako Shimizu

Takashi Watanabe

Shin-ichiro Fujii

Shinichiro Fujii

Jun Shinga

Osamu Ohara

Keisuke Ohsumi

Taku Yoshida

Masayuki Kanki

Satoru Yamasaki

Shin-Ichiro Fujii

A modified immunocyte: (1) which expresses an exogenous unmodified T cell receptor &#x3b1;-chain and an exogenous T cell receptor &#x3b2;-chain on the cell surface thereof; or (2) which contains a polynucleotide encoding a T cell receptor &#x3b1;-chain and a polynucleotide encoding a T cell receptor &#x3b2;-chain. Thus, a new tool whereby immunity can be appropriately induced in vivo is provided.

Modified immunocyte, method for producing modified immunocyte and utilization thereof

[Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of &#x3b1;-GalCer loaded on aAVC cell surface, and the amount of &#x3b1;-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.

Method for treating cancer using artificial adjuvant cell (aAVC)

The present invention provides an adjuvant that can cause immune activation or particularly T cell immune activation. The present invention provides an adjuvant that can cause particularly antigen-specific immune activation or particularly T cell immune activation.

Adjuvant composition and use thereof

The present invention provides use of KLRG1 as a marker specific to memory invariant NKT cells. Using an antibody that specifically recognizes KLRG1, memory invariant NKT cells can be easily detected or isolated.

Memory invariant NKT cell marker

A cell of the present invention contains a nucleic acid construct encoding a WT1 gene product or a fragment of the WT1 gene product. The nucleic acid construct contains (i) a region encoding a desired fragment of the WT1 gene product and (ii) only AUG as a functional start codon. The present invention can provide a cell into which the nucleic acid construct is introduced so that an expression level of a WT1 gene product or a fragment of the WT1 gene product is remarkably enhanced.

Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct

Growing community of inventors

Wako, Japan

Kanako Shimizu